title: Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.
abstract: A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.
authors.affiliation: Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Yamane
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Ochi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yasugi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tabayashi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yamagishi
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Monobe
authors.forename: Akiko
authors.initials: A
authors.lastname: Hisamoto
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Nagio
authors.initials: N
authors.lastname: Takigawa
keywords: EGFR mutation; T790M; docetaxel; non-small-cell lung cancer; pretreatment mutation